The pharmaceutical industry worldwide witnesses a dramatic regional shift to the pharmerging market, owing to the opportunities available. Considering the on-going trend of shift in global medicine dosage consumption to developing countries, about 55-60% of global consumption should come from pharmerging markets by 2021. This will eventually lead to an incremental growth of around 25% from 2016 level.

PART 01: Executive summary

PART 02: Scope of the report

Market overview

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

Highlights

PART 05: Global pharmaceutical market

Market size and forecast

PART 06: Road to pharmerging markets

PART 07: Pharmerging markets

PART 08: Market landscape

Medicine spending in emerging economies

Five forces analysis

PART 09: Market segmentation by geography

PART 10: Market overview of tier I countries

China

PART 11: Market overview of tier II countries

Brazil

Russia

India

PART 12: Market overview of tier III countries

Market size and forecast

PART 13: Market drivers

Limitations in developed economies fuels demand in

emerging economies

Increasing focus toward biosimilar in potential areas

Expansion initiatives of vendors

PART 14: Impact of drivers

PART 15: Market challenges

IP protection issues

Socio-political issues in cross geography transactions

Stringent price control and generic-centric usage lead to

value erosion

PART 16: Impact of drivers and challenges

PART 17: Market trends

Potential of new countries in emerging markets

Positive outlook toward adoption of targeted therapies

Evolving stakeholder landscape to change market

dynamics

PART 18: Vendor landscape

Competitive scenario

PART 19: Key vendor analysis

AstraZeneca

GlaxoSmithKline

Pfizer

Sanofi

Novartis

Other prominent vendors

PART 20: Appendix

List of Abbreviations

PART 21: Explore Technavio